News

KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. Morgan Stanley analyst Judah Frommer assumed coverage of the company’s stock ...
Hodgkin's lymphoma market size is expected to increase during the forecast period (2025–2034) owing to increasing incidence, advancements in ...
Detailed price information for Kymera Therapeutics Inc (KYMR-Q) from The Globe and Mail including charting and trades.
Gilead (GILD) wins the backing of an EU panel for lenacapavir, its twice-yearly injectable for prevention of HIV in ...
Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...
Insights from strategists and analysts can greatly influence market sentiment and investment strategies. CNBC's Halftime Report Final Trades discussed SNV, IYF, NEE-PR, and GILD.
TRANSFORMING a standard truck into an off road monster has been a passion project for one man and his team of genius engineers. Gregg Higgs is owner of Fab Fours, a car accessory manufacturer that ...
Gilead Sciences, Inc. today announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twice-yearly lenacapavir was effective and well ...
Gilead To Supply Lenacapavir For People In Low- And Lower-middle-income Countries July 09, 2025 — 08:15 am EDT Written by RTTNews.com for RTTNews -> ...
AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundb ...
Mount Gilead earned a boys track and field district championship on May 24, running its streak to four in a row. This is how MG pulled it off.